Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastasis: early-phase trial registry
10 of 16 indexed Metastasis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 10 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Metastasis: 16 US clinical trials tracked, 10 recruiting.
Metastasis is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is University of Texas Southwestern Medical Center, running 2 of these trials.
Enrollment posture brief
Registry condition metastasis
OPEN 10 | RECR 63% | LATE 1 | EARLY 13 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Gastroesophageal Junction Adenocarcinoma (63% recruiting · 8 trials)
Metastasis lists 10 open slots (63% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastasis is recruiting above its size-band peers.
10 of 16 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastasis trials is spread across many organizations.
University of Texas Southwestern Medical Center accounts for 2 of 16 trials (12.5%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Metastasis trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 16 trials that report a genuine target (sentinel values excluded). 10 of those (62.5%) plan for fewer than 100 participants.
-
Metastasis research is mostly interventional.
15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Merck Sharp & Dohme
NCT06863272
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma
NCT06362369
Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer
Good Samaritan Hospital Medical Center, New York
NCT05947695
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
NCT05542407
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Baptist Health South Florida
NCT05789589
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
NCT07477457
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
NCT05095207
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
University of Texas Southwestern Medical Center
NCT06712745
Definitive Radiation for High-Risk Spine Metastases
Stony Brook University
NCT06165419
Study of PAT in Patients With Solid Tumor Cancers
Masonic Cancer Center, University of Minnesota
NCT05338658
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience
NCT05103358
Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer
University of Texas Southwestern Medical Center
NCT05021237
EchoTip AcuCore Post-Market Clinical Study
Cook Research Incorporated
NCT06358001
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Nektar Therapeutics
NCT02915744
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Bristol-Myers Squibb
NCT00389155
Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
New York Presbyterian Brooklyn Methodist Hospital
NCT00374751
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastasis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastasis page
16 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Metastasis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Texas Southwestern Medical Center sponsors the most Metastasis trials on record, review their full trial history before evaluating a specific study. See University of Texas Southwestern Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastasis condition card totals 16 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.